Prostate Cancer

Focal Therapy: Patients, Interventions, and Outcomes—A Report from a Consensus Meeting

Ian A. Donaldson\textsuperscript{a,b,*}, Roberto Alonzi\textsuperscript{c}, Dean Barratt\textsuperscript{d}, Eric Barret\textsuperscript{e}, Viktor Berge\textsuperscript{f}, Simon Bott\textsuperscript{g}, David Bottomley\textsuperscript{h}, Scott Eggener\textsuperscript{i}, Behfar Ehdai\textsuperscript{j}, Mark Emberton\textsuperscript{a,b}, Richard Hindley\textsuperscript{k}, Tom Leslie\textsuperscript{l}, Alec Miners\textsuperscript{m}, Neil McCartan\textsuperscript{a}, Caroline M. Moore\textsuperscript{a,b}, Peter Pinto\textsuperscript{n}, Thomas J. Polascik\textsuperscript{o}, Lucy Simmons\textsuperscript{a,b}, Jan van der Meulen\textsuperscript{m}, Arnauld Villers\textsuperscript{p}, Sarah Willis\textsuperscript{m}, Hashim U. Ahmed\textsuperscript{a,b}

\textsuperscript{a} Division of Surgery and Interventional Science, University College London, London, UK; \textsuperscript{b} Department of Urology, UCLH NHS Foundation Trust, London, UK; \textsuperscript{c} Department of Clinical Oncology, Royal Marsden Hospital, London, UK; \textsuperscript{d} Centre for Medical Image Computing, University College London, London, UK; \textsuperscript{e} Department of Urology, L’Institut Mutualiste Montsouris, Paris, France; \textsuperscript{f} Department of Urology, Oslo University Hospital, Oslo, Norway; \textsuperscript{g} Department of Urology, Frimley Park Hospital NHS Foundation Trust, Frimley, UK; \textsuperscript{h} Institute of Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; \textsuperscript{i} Section of Urology, University of Chicago Medical Center, Chicago, IL, USA; \textsuperscript{j} Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; \textsuperscript{k} Department of Urology, Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK; \textsuperscript{l} Department of Urology, Oxford University Hospitals NHS Trust, Oxford, UK; \textsuperscript{m} Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK; \textsuperscript{n} Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; \textsuperscript{o} Division of Urology, Duke University Medical Center, Durham, NC, USA; \textsuperscript{p} Department of Urology, Hôpital Huriez, CHRU Lille, Lille, France

\textbf{Article info}

\textbf{Article history:}
Accepted September 11, 2014

\textbf{Keywords:}
Prostatic neoplasms
Consensus development conference
Organ-sparing treatments

\textbf{Abstract}

\textbf{Background:} Focal therapy as a treatment option for localized prostate cancer (PCa) is an increasingly popular and rapidly evolving field.

\textbf{Objective:} To gather expert opinion on patient selection, interventions, and meaningful outcome measures for focal therapy in clinical practice and trial design.

\textbf{Design, setting, and participants:} Fifteen experts in focal therapy followed a modified two-stage RAND/University of California, Los Angeles (UCLA) Appropriateness Methodology process. All participants independently scored 246 statements prior to rescoring at a face-to-face meeting. The meeting occurred in June 2013 at the Royal Society of Medicine, London, supported by the Wellcome Trust and the UK Department of Health.

\textbf{Outcome measurements and statistical analysis:} Agreement, disagreement, or uncertainty were calculated as the median panel score. Consensus was derived from the interpercentile range adjusted for symmetry level.

\textbf{Results and limitations:} Of 246 statements, 154 (63%) reached consensus. Items of agreement included the following: patients with intermediate risk and patients with unifocal and multifocal PCa are eligible for focal treatment; magnetic resonance imaging–targeted or template-mapping biopsy should be used to plan treatment; planned treatment margins should be 5 mm from the known tumor; prostate volume or age should not be a primary determinant of eligibility; foci of indolent cancer can be left untreated when treating the dominant index lesion; histologic outcomes should be defined by targeted biopsy at 1 yr; residual disease in the treated area of \(\leq 3 \text{ mm} \) of Gleason 3 + 3 did not need further treatment; and focal retreatment rates of \(< 20\% \) should be considered clinically acceptable but subsequent whole-gland therapy deemed...

\textsuperscript{*} Corresponding author. Division of Surgery and Interventional Science, UCL, 4th Floor Charles Bell House, 67–73 Riding House St., London W1W 7EJ, UK. Tel. +44 0 7990805676; Fax: +44 0 2076799511; E-mail address: i.donaldson@ucl.ac.uk (I.A. Donaldson).
1. **Introduction**

Focal therapy is gaining interest as a potential treatment for localized prostate cancer (PCa) [1]. In this rapidly evolving field, there is a need for robust trial designs to evaluate tissue-preserving strategies so that clinically meaningful outcomes can be presented to physicians and their patients. However, there has been much debate with respect to the ideal patient group, the type of intervention, and acceptable outcomes [2].

Researchers have been involved in a phase evaluation of focal therapy over the last 5 yr, culminating in a number of published studies summarized in a recent systematic review [1]. One of the next phases will involve greater targeting precision through the possible incorporation of accurate preoperative imaging—such as multiparametric magnetic resonance imaging (mp-MRI) to define the desired boundaries of ablation—at the time of the operative intervention.

An international consensus meeting of experts was convened to provide guidance on patient eligibility, interventions, and meaningful outcome measures for focal therapy in clinical practice and to assist in the development of a new focal therapy trial that will incorporate image fusion in the delivery of the ablative process. A number of consensus groups and panels reporting on focal therapy have used informal or formal consensus methodology [3–5]. Our current report used the formal RAND/University of California, Los Angeles (UCLA) Appropriateness Methodology as a two-stage consensus process.

2. **Methods**

The consensus panel consisted of 15 voting members, 1 independent chairperson with expertise in consensus methodology (JvdM.), and 4 nonvoting observers (I.A.D., L.S., N.M., and S.W.). Members were selected for their expertise in focal therapy and clinical trials. Their background and experience are outlined in Table 1. The meeting was supported by a grant from the Wellcome Trust and the UK Department of Health to fund the evaluation of an MRI/ultrasound fusion device for targeted biopsy and focal therapy. Available funding limited the total number of participants.

The consensus process used the RAND/UCLA Appropriateness Methodology format [6]. The 237 items on which to derive consensus were formulated in two initial small-group rounds comprising I.A.D., C.M.M., JvdM., S.W., A.M., and H.U.A., informed by current literature. Prior to a face-to-face meeting, all participants were asked to independently score these statements on a scale ranging from 1 (strongly disagree) to 9 (strongly agree).

At the face-to-face meeting, the premeeting scores were displayed graphically (Fig. 1). After discussion, each panel member independently rescored all questions. Reworking and addition of statements were allowed if the original text was considered by the group to be ambiguous or not fully comprehensive.

After the meeting, agreement levels (disagree, uncertain, agree) for each statement were calculated as the median panel score. A median of 1–3 indicated disagreement with the statement; 4–6, uncertainty; and 7–9, agreement. The level of consensus (interpanel score variation) for each statement was calculated by the interpercentile range adjusted for symmetry (IPRAS) method [6]. An IPRAS score >0 indicates consensus among the group, with higher scores indicating a stronger consensus level. Only statements reaching agreement or disagreement can be included in these recommendations.

The results presented in this paper are expert opinion and therefore constitute level 5 evidence.

3. **Results**

All participants returned questionnaires prior to the meeting, and all attended the full day. From the 237 original statements, 17 additional statements were added, 46 were reworded, and 8 were removed during the panel discussion. The removed questions were considered to be unnecessary or outside the scope of this meeting.

As a result, 246 final statements were rescored at the face-to-face meeting. Consensus was reached for 154 statements (63%), indicating agreement for 85 and disagreement for 69. The full consensus document with final statements, agreement level, and IPRAS levels is included in Supplementary Table 1.

3.1. **Definition of focal therapy**

Various minimally invasive tissue ablation strategies exist for the treatment of localized PCa [1]. In clinical trials, ablation strategies have included hemi-ablation, so-called hockey-stick ablation (extended hemi-ablation), and quadrant ablation [2]. The panel agreed that focal therapy should be defined as ablation of the dominant or index lesion only. There was agreement that quadrant ablation is a possible focal therapy strategy, but with a lower level of consensus than lesion-only ablation.

Given that the ablative pattern of brachytherapy or cryotherapy differs from that of electroproportion and high-intensity focused ultrasound, it was agreed that the morphology of the disease should guide the selection of the energy source to be used. If only one source of ablation is available, there was agreement that this situation would limit the type of focal therapy that could be delivered.
3.2. Patient selection

3.2.1. Risk
There was agreement, with a high level of consensus, that based on current National Comprehensive Cancer Network classifications [7], focal therapy should be recommended for intermediate-risk patients. There was also agreement, with a lower level of consensus, for treating men with low-risk disease.

The shift in the attitude of the group over time from providing focal treatment to low-risk patients to now treating intermediate-risk patients was discussed. The shift was thought to be in part because of growing confidence in the technique and promising medium-term follow-up results [8,9]. The group recognized concerns about overdiagnosis and overtreatment [10–12] and agreed that providing focal therapy to men with well-characterized low-risk disease would represent overtreatment and that these men may be best served with active surveillance.

3.2.2. Prostate volume
Acknowledging that some energy sources have limitations in their ability to treat some anatomic regions (eg, high-intensity focused ultrasound is limited to treating anterior lesions in small prostates only) while others do not, it was agreed that prostate volume should not be a primary determinant of eligibility for focal therapy.

3.2.3. Age and life expectancy
It was agreed that age should not be a primary determinant of focal therapy, although the panel was uncertain about whether focal treatment should be recommended for patients <40 yr or >80 yr.

The panel was also asked to evaluate criteria other than age when selecting patients eligible for focal therapy. The panel agreed that patients with a World Health Organization performance status of 0 or 1 [13] should be recommended for focal treatment and that patients with a performance status of 3 or 4 should not be recommended. There was uncertainty about treating patients with a performance status of 2.

The group agreed that focal therapy was best suited to patients with a life expectancy of >10 yr and that this therapy should not be applied to patients with a life expectancy of ≤5 yr.

3.2.4. Preintervention diagnostics
The panel agreed that a confirmatory tissue diagnosis of cancer should be available prior to performing focal therapy. There was a lack of agreement for providing focal therapy experience, Other focal therapy experience

| Panel member       | Specialty    | Center                                      | Most focal therapy experience | Other focal therapy experience |
|--------------------|--------------|---------------------------------------------|------------------------------|-------------------------------|
| Hashim U. Ahmed    | Urology      | UCLH, UK                                    | HIFU                         | Cryotherapy, PDT, Brachytherapy |
| Roberto Alonzi     | Oncology     | Royal Marsden Hospital, UK                  | Brachytherapy                | –                             |
| Eric Barret        | Urology      | L’Institut Mutualiste, Montsouris, France   | Cryotherapy, HIFU, PDT        | –                             |
| Viktor Berge       | Urology      | Oslo University Hospital, Norway            | HIFU                         | –                             |
| Simon Bott         | Urology      | Frimley Park Hospital, UK                   | HIFU                         | Cryotherapy, PDT, Brachytherapy |
| David Bottomley    | Oncology     | Leeds Teaching Hospitals, UK                | Brachytherapy                | –                             |
| Scott Eggener      | Urology      | University of Chicago Medical Centre, USA   | Laser photothermal           | –                             |
| Behfar Ehdaie      | Urology      | Memorial Sloan Kettering Cancer Center, USA | Cryotherapy, Electroporation | HIFU Brachytherapy            |
| Mark Emberton      | Urology      | UCLH, UK                                    | HIFU                         | Electroporation, PDT, Cryotherapy |
| Richard Hindley    | Urology      | Hampshire Hospitals, UK                     | HIFU                         | PDT, Cryotherapy              |
| Tom Leslie         | Urology      | Oxford University Hospitals, UK             | HIFU                         | PDT, Brachytherapy            |
| Caroline M. Moore  | Urology      | UCLH, UK                                    | HIFU                         | PDT, Brachytherapy            |
| Peter Pinto        | Urology      | NIH, USA                                    | Laser photothermal           | HIFU Brachytherapy            |
| Thomas J. Polascik  | Urology      | Duke University Medical Centre, USA         | Cryotherapy, Electroporation | –                             |
| Arnauld Villers    | Urology      | CHRU Lille, France                          | HIFU                         | PDT, Brachytherapy            |

HIFU = high-intensity focused ultrasound; NIH = National Institutes of Health; PDT = photodynamic therapy; UCLH = University College London Hospital.
treatment without a biopsy, given that the true positive predictive value of mp-MRI is yet to be fully quantified.

It was agreed that focal therapy can be performed in patients who have undergone an MRI-targeted prostate biopsy and in patients who have had a standard transrectal ultrasound (TRUS) biopsy in which the positive cores reflect, and are concordant with, a high-quality mp-MRI reported by an expert radiologist. When using an MRI-targeted strategy, the Standards of Reporting for MRI-targeted Biopsy Studies guidelines [14] should be followed.

3.2.5. Disease visualization

For patients who have not had an mp-MRI because of lack of availability or physician preference, it was agreed that only a full transperineal template–mapping biopsy was sufficient to perform focal therapy [15]. The panel did not agree that the delivery of focal therapy can be based on only the information from a standard or extended TRUS biopsy without further imaging or template-mapping biopsies.

3.2.6. Previous treatment

The panel agreed that focal therapy can be applied in patients who have already undergone one focal therapy and in patients who have had previous whole-gland treatment. In addition, focal therapy does not need to be limited to patients with a primary diagnosis of PCa and can be used in the setting of radiorecurrent disease [16] when the recurrent disease can be accurately localized.

3.3. Intervention

3.3.1. Setting

The panel agreed that ideally, focal therapy should be delivered as a day case procedure, and it can be delivered in an office-based setting if the necessary equipment is in place.

3.3.2. Multifocality

Specifically addressing the question of multifocal cancer, there was agreement that therapy should be targeted to the index lesion. There was no agreement about whether focal therapy should be targeted to all lesions. However, the panel agreed that multifocal cancer should not preclude focal therapy.

3.3.3. Untreated disease

PCa is predominantly multifocal in the vast majority of men. The multifocal nature of PCa will mean that when using a focal therapy strategy to treat the primary PCa, some disease will be left untreated. As a result, the concept of index lesion ablation or ablation of one large, high-grade lesion has been proposed as a manner by which most men might undergo focal therapy [17]. At the heart of what threshold of disease clinicians are willing to leave untreated is the definition of what constitutes clinically significant disease.

The panel agreed that it was acceptable not to treat lesions of Gleason grade 3 + 3 up to a maximum cancer core length of 5 mm, although it has to be noted that the level of consensus was higher for not treating lesions with a smaller maximum cancer core length of 3 mm.

The panel agreed that it is not acceptable to leave untreated lesions with Gleason grade 3 + 4 with a maximum cancer core length of 5 mm or any 4 + 3 disease of any length. However, the panel did not reach consensus on whether lesions with Gleason grade 3 + 4 with a maximum cancer core length of 3 mm could be left untreated.

3.3.4. Tumor volume

The panel did not agree on a maximum tumor volume beyond which focal therapy is deemed not suitable. Other factors needed to be considered, including the size of the prostate, the grade of the lesion, and the boundaries and morphologic characteristics of the lesion.
3.3.5. Therapy planning
The panel agreed that ≤3 mm was an acceptable targeting error for software delivery of focal therapy to the center of the lesion. When performing focal therapy, an optimal circumferential margin for treatment was deemed to be 5 mm around a lesion that was seen on imaging. This is concordant with evidence that a targeting error in the order of 2–3 mm will achieve a positive hit rate of 90–95% of a 0.5-ml tumor and that MRI can underestimate tumor volume [18,19].

3.3.6. Mode of treatment
In an attempt to define which treatment modality was preferred, multiple clinical scenarios were presented to the panel members. No clear preference emerged, with the discussion surrounding the idea that there is not enough evidence to support one treatment modality over another, and the best modality is the one that is available to the clinician and that the clinician has experience delivering.

3.4. Outcome
3.4.1. Residual cancer
When using focal therapy to treat localized PCAs, there is potential for cancer to remain within the intended treatment zone. The panel agreed that cancer in the treatment zone of Gleason grade 3 + 3 with a cancer core length ≤3 mm is clinically acceptable, but only if there is a decrease from the original cancer burden. In other words, the original cancer lesion should be of a higher grade or higher volume than the cancer that remains in the treatment field. Remaining lesions of Gleason grade 3 + 4 or 4 + 3 are never clinically acceptable, regardless of cancer core length.

3.4.2. Post treatment biopsy
It was agreed that the optimal time for the first prostate biopsy after focal treatment is at 1 yr. A rising prostate-specific antigen level or suspicious areas on mp-MRI should also trigger biopsy. Patients who have had brachytherapy may need to wait 2 yr. The panel agreed that the biopsy should be performed in a targeted manner, as otherwise, previously untreated tissue could easily be inadvertently sampled. The panel remained uncertain about whether posttreatment biopsy should also routinely sample the untreated gland.

3.4.3. Retreatment
The panel agreed that retreatment rates of ≤20% with focal therapy were clinically acceptable. There was agreement that any subsequent whole-gland therapy reflects a failure of focal therapy. A retreatment rate of ≤10% with whole-gland therapy was considered to be clinically acceptable.

4. Discussion
4.1. Summary of findings
The results of our consensus exercise following the RAND/UCLA Appropriateness Methodology provide guidance to clinicians who deliver focal therapy to patients with localized PCAs. The results are also helpful to clinical researchers when planning studies evaluating the effectiveness of focal treatment compared with other treatment options.

4.2. Clinical and research implications
Our consensus panel agreed on a number of key points, which all represent a significant shift in the thinking about the potential role of focal treatment for patients with localized PCAs. A first example is that the panel recommended focal therapy for men with intermediate-risk PCAs. Also, the panel expressed the view that any energy modality could be used, provided that the capability of the ablative modality and the characteristics of the disease were taken into account when planning the treatment. Finally, it was agreed that focal treatment could be used for multifocal disease, secondary lesions ≤5 mm of Gleason 3 + 3 could be left untreated, and a reduction of grade or burden of disease within the treated area reflects treatment success. When selecting candidates for focal therapy, it is important that they be properly characterized. Reports of Gleason pattern 6 metastasizing exist [20] but have occurred in high-risk individuals who have undergone systemic therapy and would not be selected for focal treatment.

A number of uncertainties were identified and should be the topic of future research. The research questions include whether one therapeutic modality is better than another in terms of the ratio of side effects to cancer control, whether low-volume Gleason pattern 4 could be left untreated, and whether focal therapy compromises the application of a subsequent radical therapy in those men who might require it.

Whether longer-term comparative randomized studies can be delivered to answer these questions is an open question [21]. There remains significant skepticism on whether such a study is feasible in both ability to recruit and randomize and in terms of the size that would be required to demonstrate noninferiority of focal therapy compared with radical therapy, especially when survival is considered.

4.3. Limitations
Expert group meetings can be prone to significant bias since by their nature, they are composed of people who might have a vested interest in the field as a whole or in particular aspects of it. The presence of an independent chair, who had no personal interest in the results of the consensus exercise and who ensured that all panel members had the opportunity to contribute to the discussions and that no member dominated the discussions, reduced this bias. It is also important to note that the scoring method—also during the face-to-face meeting—was anonymous. We also acknowledge that there was a lack of expertise in imaging and pathology. Although this situation was decided a priori because the questions were about delivery of focal therapy, it may have affected our findings.
5. Conclusions

PCa treatment is evolving with the emergence of new ablative technologies and techniques. Guidance formulated using consensus methodology assists clinicians delivering focal therapy and helps inform future clinical trials and research programs. In this paper we have identified criteria for those men who may be suitable for focal therapy and disease states that could be treated, and we have outlined therapy-planning strategies and outcomes that might be legitimate and acceptable for clinical adoption if successfully met in prospective cohorts and trials.

Author contributions: Ian A. Donaldson had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Donaldson, Moore, Willis, Miners, Barratt, van der Meulen, Emberton, Ahmed.

Acquisition of data: Donaldson, Alonzi, Barret, Berge, Bort, Bottomley, Eggener, Ehdaiie, Emberton, Hindley, Leslie, Moore, Pinto, Polascik, van der Meulen, Villers, Ahmed.

Analysis and interpretation of data: Donaldson, Willis.

Drafting of the manuscript: Donaldson.

Critical revision of the manuscript for important intellectual content: Donaldson, Alonzi, Barret, Berge, Bort, Bottomley, Eggener, Ehdaiie, Emberton, Hindley, Leslie, Moore, Pinto, Polascik, van der Meulen, Villers, Ahmed.

Statistical analysis: Donaldson, Willis.

Obtaining funding: None.

Administrative, technical, or material support: McCartan, Simmons.

Supervision: None.

Other (specify): None.

Financial disclosures: Ian A. Donaldson certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Ian A. Donaldson receives funding from the Department of Health, UK, and the Wellcome Trust. Dean Barratt is an investigator on projects funded by the Department of Health, UK; the Wellcome Trust; Prostate Cancer UK; the National Institute of Health Research, UK; and the UK Engineering and Physical Sciences Research Council. He has served as an unpaid consultant for SonaCare Medical LLC. Mark Emberton is a consultant to SonaCare Medical LLC, Steba Biotech, Sanofi Aventis, GlaxoSmithKline, Angiodynamics, and Sophiris. Neil McCartan has provided consultancy services for Steba Biotech and SonaCare Medical LLC. Caroline M. Moore receives funding from GlaxoSmithKline, the Wellcome Trust, Advanced Medical Diagnostics, and Sanofi and is a consultant for Steba Biotech. Thomas J. Polascik is a member of the board of the COLD registry and a consultant for Endocare. He is also an investigator for a clinical trial on Nanoknife (Angiodynamics). Sarah Willis receives funding from the Department of Health, UK, and the Wellcome Trust. Hashim U. Ahmed receives funding from the Wellcome Trust, National Institutes of Health Research–Health Technology Assessment program, the US National Institutes of Health–National Cancer Institute, Prostate Action Medical Research Council (UK), and Prostate Cancer Research Centre; he also receives funding from SonaCare Medical LLC, Misonix, Oncura, and GE Healthcare for medical consultancy and is a consultant to Steba Biotech.

Funding/Support and role of the sponsor: The Department of Health, UK, and the Wellcome Trust had a role in the preparation and approval of the manuscript. This publication presents independent research supported by the Health Innovation Challenge Fund (HICF-T4–310), a parallel funding partnership between the Department of Health, UK, and the Wellcome Trust. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health or the Wellcome Trust.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.eururo.2014.09.018.

References

[1] Valerio M, Ahmed HU, Emberton M, et al. The role of focal therapy in the management of localised prostate cancer: a systematic review. Eur Urol 2014;66:732–51.

[2] Kasivisvanathan V, Emberton M, Ahmed HU. Focal therapy for prostate cancer: rationale and treatment opportunities. Clin Oncol 2013;25:461–73.

[3] Van den Bos W, Muller BG, Ahmed H, et al. Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. Eur Urol 2014;65:1078–83.

[4] Ahmed HU, Akin O, Coleman JA, et al. Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int 2012;109:1636–47.

[5] Rosette J de la, Ahmed H, Barentsz J, et al. Focal therapy in prostate cancer—report from a consensus panel. J Endoul 2010;24:775–80.

[6] Fitch K, Bernstein SJ, Aguilar MD, et al. The RAND/UCLA Appropriateness Method user’s manual. Santa Monica, CA: RAND Corporation; 2001.

[7] Mohler JL, Armstrong AJ, Bahnsen RR, et al. NCCN clinical practice guidelines in oncology—prostate cancer. Fort Washington, PA: National Comprehensive Cancer Network; 2012.

[8] Bahn D, de Castro Abreu AL, Gill IS, et al. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol 2012;62:55–63.

[9] Ahmed HU, Hindley RG, Dickinson I, et al. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol 2012;13:622–32.

[10] Wilt TJ, Ahmed HU. Prostate cancer screening and the management of clinically localized disease. BMJ 2013;325:1–9.

[11] Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203–13.

[12] Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;157:120–34.

[13] Oken MM, Creech RH, Torreyme DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–55.

[14] Moore CM, Kasivisvanthan V, Eggener S, et al. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an international working group. Eur Urol 2013;64:544–52.

[15] Singh PB, Anele C, Dalton E, et al. Prostate cancer tumour features on template prostate-mapping biopsies: implications for focal therapy. Eur Urol 2014;66:12–9.

[16] Kanthabalan A, Arya M, Punwani S, et al. Role of focal salvage ablative therapy in localised radiorecurrent prostate cancer. World J Urol 2013;31:1361.
[17] Ahmed HU. The index lesion and the origin of prostate cancer. N Engl J Med 2009;361:1704–6.

[18] Hu Y, Ahmed HU, Taylor Z, et al. MR to ultrasound registration for image-guided prostate interventions. Med Image Anal 2012;16: 687–703.

[19] Cornud F, Khoury G, Bouazza N, et al. Tumor target volume for focal therapy of prostate cancer—does multiparametric magnetic resonance imaging allow for a reliable estimation? J Urol 2014; 191:1272–9.

[20] Haffner MC, Mosbruger T, Esopi DM, et al. Tracking the clonal origin of lethal prostate cancer. J Clin Invest 2013;123:2–6.

[21] Ahmed HU, Berge V, Bottomley D, et al. Can we deliver randomized trials of focal therapy in prostate cancer? Nat Rev Clin Oncol 2014;11:482–91.